Archive for the CTI Clinical Trial & Consulting Services Inc. Category

{PRESS RELEASE, PIX, CINCINNATI ENQUIRER STORY, FOTO SHOOT VIDEO} ~~ ‘CTI Finds Niche in the Quest for Cures’ ~~ Cincinnati Enquirer cover story today, CTI Clinical Trial and Consulting Services ~~ 3.21.14 ~~ thanks to Val Prevish (@vprevish), Lee Ann Hamilton (@leeannhamilton) and The Cincinnati Enquirer (@enquirer) !!

Posted in CTI Clinical Trial & Consulting Services Inc. with tags , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , on 03/21/2014 by @CincinnatiPR

Press Release: CTI Clinical Trial and Consulting Services – 15 Years of Life Changing Therapies – 3.21.14 Press Release by Andy Hemmer

{Enquirer link:}

 {http://www.cincinnati.com/story/money/2014/03/20/cti-finds-niche-quest-cures/6672407/}

{PDF —>>> CTI Clinical Trial and Consulting Services in Cincinnati Enquirer 3.21.14 PR by Andy Hemmer}

 Success spurs international expansion from North America to Europe and Latin America.

New era: CTI tapped for groundbreaking Stem Cell and Regenerative Medicine work.

Dozens of new trials launched including five ‘First-in-Human’ trials.

[CINCINNATI, Ohio ~ March 21, 2014] From the outside looking in, a “Contract Research Organization” (CRO) such as CTI Clinical Trial & Consulting Services is an organization providing support to the pharmaceutical, biotechnology, and medical-device industries.

Simple enough.

But to the people touched by the efforts of CTI and its global force of staff researchers, physicians, nurses pharmacists and associated health care professionals, however, this privately-held, deeply passionate company and its people represent something so much more: specifically, life-changing therapies.

Celebrating its 15th year in 2013, the work performed by CTI throughout North America, Europe, and Latin America still attracts the biggest and the best, serving more than 70 large and mid-sized pharmaceutical and biotechnology companies, including eight of the 10 largest globally.

International giants such as Astellas Pharma Inc. of Tokyo, Japan, formerly known as Fujisawa, and Genentech Roche of Switzerland have been clients since Day One.

CTI was founded by a Cincinnati native who’s a former University of Cincinnati Professor, Timothy J. Schroeder and Lynn Fallon, a former transplant nurse, administrator, and pharmaceutical executive.

The company’s niche mirrors the unique skills of its founders: combining expertise of clinical knowledge and market experience, CTI is uniquely positioned to incorporate both clinical and market-driven endpoints and interpretations to provide results.

CTI has worked on more than 1,200 projects, contributing to more than 30 new drug approvals working with the Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other global regulatory agencies.

CTI is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations.

Life-Saving, Life-Changing

 The driving force for today’s internationally-focused CTI is a passion for the life-saving and life-changing opportunities afforded in the explosive areas of regenerative medicine and the stem cell marketplace.

Regenerative medicine presents enormous opportunity for mankind, and industry.

CTI helps clients navigate regulatory hurdles, and understands the complex logistics involved with conducting clinical research studies.

Major advances are being made every day in diseases that are currently untreatable, and will continue to be made in the very near future,” said Schroeder, “and CTI will continue to play a significant role.”

While the future for CTI will encompass the company’s traditional sweet spots – clinical trial management, regulatory pathway design, data/market analysis including health economics, and consulting services – its focus is still on life-saving therapies, including regenerative medicine, specifically gene and stem cell therapies.

Throughout my career, trends and science and technology are forever introducing us to new ideas, new ways for us to perform better, faster, with more meaningful results,” Schroeder said, “but nothing can touch what’s going on with stem cell therapies.

We believe in the next 10-15 years the current medical and surgical approaches to disease management will include a third pillar, which is regenerative medicine,” said Schroeder.

CTI: Still a family

Despite its international reach, CTI is run like a family.

CTI works with the same Cincinnati-based bank, accounting firm, law firm, and printing company it had in 1999.

The firm is deeply dedicated to training, with employees logging at least 100 hours annually.

CTI has a 95 percent workforce retention rate, in 17 states and 15 countries. It’s currently looking to fill positions in North America, Europe, and Latin America.

CTI {http://www.CTIFacts.com photo shoot with The Cincinnati Enquirer.

CTI {http://www.CTIFacts.com} photo shoot with The Cincinnati Enquirer.

Schroeder opened CTI in 1999 in a tiny office in Clifton, an uptown Cincinnati neighborhood, right down the street from his old employer, the University of Cincinnati.

As a Professor, Schroeder instructed on a wide range of subjects from health care and life sciences, often combining the two. The early years focused on North American work, and clients.

As the company’s reputation, network and bench strength grew – headquartered in Cincinnati (Blue Ash), with U.S. offices in Raleigh and Philadelphia, along with a string of European offices headquartered in Ulm, Germany – aforementioned work and client referrals transformed CTI into the innovative and international drug and device development organization it is today.

CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious diseases, hematology, cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential.

For more information, please visit www.CTIFacts.com.

For media inquiries of CTI, please contact Mr. Andy Hemmer, TheWritingFiend@Large and President of AndyHemmer.com PR at (513) 604-5428 or andy@andyhemmer.com.

# 30 #

Contact:

Allison L. Schroeder

Associate Manager, Marketing & Corporate Communications

CTI Clinical Trial and Consulting Services

10123 Alliance Road

Cincinnati, OH 45242

(513) 598-9290

aschroeder@ctifacts.com

(Story, VIDEOS, Press Release, Photo) ~ CTI Clinical Trial and Consulting Services Inc. in The Cincinnati Business Courier today: acquisition of S2 Statistical Solutions. Starring CTI President, CEO Tim Schroeder; S2 Statistical Solutions President, Founder Dr. Candace Gunnarsson; and CTI EVP (President of Consulting) Lynn Fallon. Thanks to Reporter James Ritchie (@JamesCinciBiz) and The Cincinnati @BusinessCourier!

Posted in CTI Clinical Trial & Consulting Services Inc. with tags , , , , , , , , , on 06/21/2013 by @CincinnatiPR

Cincinnati Business Courier story onlinehttp://www.bizjournals.com/cincinnati/blog/2013/06/clinical-trials-firm-makes-cincinnati.html

Press Release as PDFCTI Clinical Trial and Consulting Services acquires S2 Statistical Solutions – Press Release – 6.13.13

CTI Clinical Trial and Consulting Services (CTI), a global, privately held, full-service contract research organization announces the acquisition of S2 Statistical Solutions (S2). S2, a renowned health outcomes and health economics organization, focuses on the power of analytics through data mining and economic research.

S2 specializes in generating and interpreting evidence from large databases and then publishing it in the most effective, high-impact venues, including various peer reviewed publications.

S2 has been partnering with pharmaceutical, medical device, and diagnostic companies for over a decade, providing innovative outcome and economic analyses, models, visualization programs, systematic literature reviews, and meta analyses.

Dr. Candace Gunnarsson, the founder of S2, will be joining CTI (www.CTIfacts.com) along with her entire team.

I am very excited to combine forces with CTI and I know that we will be able to achieve great things together. Our principles, work ethic and expertise truly complement the CTI Team,” states Dr. Candace Gunnarsson, President of S2.

According to Lynn Fallon, Executive Vice President and President, Consulting Services at CTI, “The S2 team members are incredibly accomplished with top-ranked scientists, health economists, and statisticians, and will join Dr. William Irish, CTI’s Vice President of Health Outcomes and Biostatistics, as well as the rest of our team at CTI.

“We firmly believe that health outcomes and economics are critically important to both our biotechnology and pharmaceutical clients. This merger strengthens our service offerings from the early development stages of drugs and devices through Phase 3 and commercialization.

Investors often require companies to build economic models to provide product valuation, even in early development. Health economics is also proving particularly important to the many orphan disease programs that CTI is leading,Fallon concluded.

The terms of the acquisition were not disclosed.

Plante Moran and Fifth Third Bank provided support to CTI, while Graydon, Head and Ritchey assisted S2. 

For media inquiries regarding CTI Clinical Trial and Consulting Services, please contact Mr. Andy Hemmer, President of AndyHemmer.com PR and TheWritingFiend@Large at (513) 604-5428 or andy@andyhemmer.com.

About CTI Clinical Trial and Consulting Services

CTI Clinical Trial and Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in transplantation, immunology, infectious   diseases, hematology,  cardiology, nephrology, hepatology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, OH; CTI has offices in North America, Europe and South America.

%d bloggers like this: